Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 299-302

  De Rycke, L ^a   Verhelst, X ^a   Kruithof, E ^a   Van Den Bosch, F ^a   Hoffman, I E A ^a   Veys, E M ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13244261140     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.023523     Document Type: Article

References (15)

1. De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
2. Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1082-8.
3. Hill JA, Southwood S, Sette A, Jevnikar A, Bell DA, Cairins E. Cutting edge: the conversion of arginine to citrulline allows for a high affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
4. Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 1990;33:1156-61.
5. Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990;33:19-28.
6. Olsen NJ, Teal GP, Brooks. IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions 1991;34:169-71.
7. Feldmann M, Maini RN. Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002;69:12-18.
8. De Rycke L, Kruithof E, Van Damme N, Hoffman IEA, Van Den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis and spondyloarthropatny. Arthritis Rheum 2003;48:1015-23.
9. Arnett FC, Edworthy SM, Bloch DA McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
11. Bas S, Perneger TV, Seite M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic test for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002;41:809-14.
12. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties af rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
13. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:197-204.
14. Maini R, William St Clair E, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concommitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
15. Charles P, Smeenk RJT, De Jong J, Feldmann M, Maini R. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to rumor necrosis factor α. Arthritis Rheum 2000;11:2383-90.